The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Edwards Lifesciences Corp

NYSE: EW
Last

(U.S.) $131.40

Today's change+1.66 +1.28%
Updated December 18 4:01 PM EST. Delayed by at least 15 minutes.
 

Edwards Lifesciences Corp

NYSE: EW
Last

(U.S.) $131.40

Today's change+1.66 +1.28%
Updated December 18 4:01 PM EST. Delayed by at least 15 minutes.

Edwards Lifesciences Corp up (U.S.)$1.66

Edwards Lifesciences Corp closed up Thursday by (U.S.)$1.66 or 1.28% to (U.S.)$131.40. Shares have lost 0.51% over the last five days, but sit 2.15% below their 52-week high. This security has outperformed the S&P 500 by 92.28% during the last year.

Key company metrics

  • Open(U.S.) $130.96
  • Previous close(U.S.) $129.74
  • High(U.S.) $131.43
  • Low(U.S.) $129.89
  • Bid / Ask-- / --
  • YTD % change+99.82%
  • Volume1,294,351
  • Average volume (10-day)1,301,087
  • Average volume (1-month)1,006,946
  • Average volume (3-month)944,635
  • 52-week range(U.S.) $62.56 to (U.S.) $134.29
  • Beta0.62
  • Trailing P/E18.24×
  • P/E 1 year forward38.32×
  • Forward PEG2.59×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $7.20
Updated December 18 4:01 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+34.70%

Based on its net profit margin of 34.70%, Edwards Lifesciences Corp is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.93%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue607575522536
Total other revenue--------
Total revenue607575522536
Gross profit439424377391
Total cost of revenue168151146146
Total operating expense487-238445435
Selling / general / administrative222216197191
Research & development88898679
Depreciation / amortization--------
Interest expense (income), net operating4455
Unusual expense (income)4-697916
Other operating expenses, total1000
Operating income12181377102
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax12181377102
Income after tax955476076
Income tax, total262661726
Net income955476076
Total adjustments to net income--------
Net income before extra. items955476076
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items955476076
Inc. avail. to common incl. extra. items955476076
Diluted net income955476076
Dilution adjustment00--0
Diluted weighted average shares108107109111
Diluted EPS excluding extraordinary itemsvalue per share0.875.090.560.68
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.900.730.620.79